Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) EBT (2018 - 2025)

Exagen (XGN) has disclosed EBT for 8 consecutive years, with -$6.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 67.03% year-over-year to -$6.3 million, compared with a TTM value of -$21.5 million through Dec 2025, down 42.37%, and an annual FY2025 reading of -$19.9 million, down 31.76% over the prior year.
  • EBT was -$6.3 million for Q4 2025 at Exagen, up from -$7.1 million in the prior quarter.
  • Across five years, EBT topped out at -$3.0 million in Q2 2024 and bottomed at -$15.1 million in Q4 2022.
  • Average EBT over 5 years is -$6.8 million, with a median of -$6.2 million recorded in 2021.
  • The sharpest move saw EBT plummeted 128.86% in 2022, then soared 65.83% in 2023.
  • Year by year, EBT stood at -$6.9 million in 2021, then plummeted by 119.79% to -$15.1 million in 2022, then skyrocketed by 63.35% to -$5.5 million in 2023, then soared by 32.33% to -$3.7 million in 2024, then plummeted by 67.03% to -$6.3 million in 2025.
  • Business Quant data shows EBT for XGN at -$6.3 million in Q4 2025, -$7.1 million in Q3 2025, and -$4.4 million in Q2 2025.